arrow
R

Roberto Marasca

university of modena and reggio emilia
H指数:62
被引数:1.3万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

A Trajectory-Adaptive Model of Early Palliative Care in AML and High-Risk MDS: Real-World Evidence on Core Components and Care Outcomes

急性髓系白血病和高风险骨髓增生异常综合征早期姑息治疗的轨迹适应性模型:关于核心组成和护理结局的真实世界证据

2026-09-300
OA
Pirtobrutinib in Richter syndrome: Outcomes from the named patient programme in Italy

吡柔比星在里奇特综合征中的应用:来自意大利指定患者项目的结果

2026-09-060
OAAI
Fixed-duration VenO vs FCR/BR in fit patients with untreated CLL: primary analysis of the phase 3 CRISTALLO trial

固定疗程维奈克拉 vs FCR/BR 在初治慢性淋巴细胞白血病患者中的疗效:CRISTALLO III期试验主要分析

Blood
IF23.1
2026-03-040
OA
Nilotinib versus imatinib with early switch from imatinib to nilotinib to obtain treatment-free remission in newly diagnosed chronic myeloid leukemia patients: the analysis of the first co-primary endpoint

尼洛替尼与伊马替尼治疗新诊断慢性髓性白血病患者的比较,包括早期从伊马替尼转换为尼洛替尼以实现治疗缓解的首次主要终点分析

Leukemia
IF13.4
2025-11-180
OAAI
Identification of four autophagy-related genetic variants as risk factors for chronic lymphocytic leukemia

鉴定四种自噬相关遗传变异为慢性淋巴细胞白血病的风险因素

2025-09-050
OAAI
The prognostic value of health-related quality of life for early molecular response in patients with chronic myeloid leukemia: analysis of the GIMEMA-SUSTRENIM trial

健康相关生活质量对慢性髓性白血病患者早期分子应答的预测价值:GIMEMA-SUSTRENIM试验分析

2025-08-270
OA
Venetoclax-based regimens in octogenarian patients with CLL: efficacy, safety, and comparison to BTKi in a multicenter cohort

基于维奈克拉茨方案的八旬慢性淋巴细胞白血病患者:疗效、安全性及与BTKi的比较(多中心队列研究)

2025-04-240
OA
Early Palliative Care, Goals of Care Conversations and Quality EOL Care in Acute Leukemia and HR-MDS

早期姑息治疗、照护目标讨论和急性白血病及HR-MDS中的临终关怀质量

2025-04-030
PRE
Distribution of different classes of CSF3R mutations and co-mutational pattern in 360 myeloid neoplasia
2025-02-050
OAAI
CRISTALLO: Results from a Phase III Trial of Venetoclax-Obinutuzumab Versus Fludarabine, Cyclophosphamide and Rituximab or Bendamustine-Rituximab in Patients with Untreated Chronic Lymphocytic Leukemia without Del(17p) or TP53 Mutations

CRISTALLO:一项关于Venetoclax-Obinutuzumab与Fludarabine、Cyclophosphamide和Rituximab或Bendamustine-Rituximab治疗无Del(17p)或TP53突变初治慢性淋巴细胞白血病患者Ⅲ期试验的结果

BLOOD
IF23.1
2024-11-050
PRE
CD49d expression is included in a revised 4-factor model predicting outcome in patients with chronic lymphocytic leukemia treated with ibrutinib: A multicenter real-world experience
2024-07-151
OAAI
NFKBIE mutations are selected by the tumor microenvironment and contribute to immune escape in chronic lymphocytic leukemia
LEUKEMIA
IF13.4
2024-03-154
OAAI
The evolving landscape of COVID-19 and post-COVID condition in patients with chronic lymphocytic leukemia: A study by ERIC, the European research initiative on CLL

慢性淋巴细胞白血病患者新型冠状病毒肺炎和COVID后病情的演变: 欧洲CLL研究计划ERIC的一项研究

2023-09-2911
OAAI
BTK and PLCG2 remain unmutated in one-third of patients with CLL relapsing on ibrutinib

BTK和PLCG2在接受依鲁替尼治疗的CLL复发患者的3分之1中保持未突变

2023-06-1638
OAAI
Clinical impact of TP53 disruption in chronic lymphocytic leukemia patients treated with ibrutinib: a campus CLL study
LEUKEMIA
IF13.4
2023-02-1813
OAAI
High rate of durable responses with undetectable minimal residual disease with front-line venetoclax and rituximab in young, fit patients with chronic lymphocytic leukemia and an adverse biological profile: results of the GIMEMA phase II LLC1518-VERITAS study
2023-01-125
OAAI
The dynamic functions of IRF4 in B cell malignancies

IRF4在b细胞恶性肿瘤中的动态功能

2022-12-1012
OAAI
Feasibility of autologous peripheral blood stem cell mobilization and harvest in adult patients with FLT3-mutated acute myeloid leukemia receiving chemotherapy combined with midostaurin: a single-center experience
2022-10-200
PRE
Long-term benefit of IGHV mutated patients in a real-life multicenter cohort of FCR-treated chronic lymphocytic leukemia

在FCR治疗的慢性淋巴细胞白血病的真实多中心队列中,IGHV突变患者的长期益处

2022-10-103
PRE